ERBB2 and neoplasm: In terms of receptor profile expression, inferior BCSS was found to be associated with ER+HER2+ (HR 1.51 (95% c.i. 1.12 to 2.02), P = 0.007) and ER−HER2− (HR 1.41 (95% c.i. 1.01 to 1.97), P = 0.042) tumours; however, this did not impact survival outcomes in adjusted analysis.